The funds will be used for the development of a novel drug for endometriosis treatment. The company’s lead program, HSD17B1 Inhibitor FOR-6219, is entering phase I studies during second quarter of 2018.
Founded in 2013 and led by CEO Risto Lammintausta, Forendo Pharma is a held drug development company, with core competences in modulating tissue specific hormone mechanisms. The company’s pipeline includes HSD17B1 inhibitors (preclinical) for the treatment of endometriosis; dual HSD inhibitors (discovery) for the treatment of endometriosis, with potential for other endocrinological diseases; and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions.
Forendo is backed by Novo Seeds, Karolinska Development, Novartis Venture Fund, M Ventures and Innovestor.